The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a more substantial reduction in body size and enhance metabolic health, part… Read More